Skip to contents

Aaron S. Kesselheim, MD, JD, MPH
Associate Physician, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Phar Epid & Phar Econ
75 Francis Street
Boston, MA 02115

Research Location: One Brigham Circle

Edit Profile

Research Narrative:

Aaron S. Kesselheim, MD, JD, MPH, is a Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Within the Division, Dr. Kesselheim leads the Program On Regulation, Therapeutics, And Law (PORTAL), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. PORTAL conducts research on empirical and normative research in legal, ethical, and policy issues regarding the development, approval, and evidence-based use of drugs, devices, vaccines, procedures, and diagnostics. Particular areas of focus include regulation, intellectual property, and comparative effectiveness. These topics are addressed through a variety of descriptive, qualitative, and quantitative methodologies.

Harvard School of Public Health, 2007, MPH
University of Pennsylvania School of Medicine, 2002, MD
University of Pennsylvania Law School, 2002, JD

Publications (Pulled from Harvard Catalyst Profiles):

1. Stern AD, Pietrulla F, Herr A, Kesselheim AS, Sarpatwari A. The Impact Of Price Regulation On The Availability Of New Drugs In Germany. Health Aff (Millwood). 2019 Jul; 38(7):1182-1187.

2. Kramer DB, Kesselheim AS. Trust and transparency in medical device regulation. BMJ. 2019 06 18; 365:l4166.

3. Dave CV, Brill G, Kesselheim AS. Changes in Price for Generic Drugs in the USA, 2008-2016. J Gen Intern Med. 2019 May 07.

4. Bollyky T, Kesselheim AS. Pharmaceutical Protections in U.S. Trade Deals - What Do Americans Get in Return? N Engl J Med. 2019 May 23; 380(21):1993-1995.

5. Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly JG, Fischer MA, Kesselheim AS, Gagne JJ. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS Med. 2019 Mar; 16(3):e1002763.

6. Bourgeois FT, Graham DA, Kesselheim AS, Randolph AG. Cost Implications of Escalating Intravenous Acetaminophen Use in Children. JAMA Pediatr. 2019 Mar 11.

7. Darrow JJ, Beall RF, Kesselheim AS. The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents. Appl Health Econ Health Policy. 2019 Feb; 17(1):47-54.

8. Kesselheim AS, Woloshin S, Lu Z, Tessema FA, Ross KM, Schwartz LM. Internal Medicine Physicians' Financial Relationships with Industry: An Updated National Estimate. J Gen Intern Med. 2019 Feb; 34(2):195-197.

9. Hwang TJ, Bourgeois FT, Franklin JM, Kesselheim AS. Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases. Health Aff (Millwood). 2019 Feb; 38(2):313-319.

10. Kesselheim AS, Woloshin S, Lu Z, Tessema FA, Ross KM, Schwartz LM. Physicians' Perspectives on FDA Approval Standards and Off-Label Drug Marketing. JAMA Intern Med. 2019 Jan 22.